Abstracts tagged "IL-6"

Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Virginia Ruiz-Esquide¹, Azucena Gonzalez-Navarro², Jordi Yagüe³, Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Julio Ramirez¹, Sonia Cabrera-Villalba¹, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Eun Chung Hong¹, Hemin Jeong², Jiwon Hwang², Eun-Kyung Bae¹, Hyungjin Kim², Joong Kyong Ahn³, Hoon-Suk Cha², Eun-mi Koh⁴ and Jaejoon Lee⁴, ¹Samsung Biomedical Research Institute, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Sungkyunkwan univ. school of medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…
Abstract Number: 2345 • 2014 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis
Hiroto Yoshida, Mika Yagoto, Miho Suzuki, Keisuke Tanaka, Misato Hashizume and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is…
Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst³, Abraham Rutgers², Annemieke M.H. Boots⁴ and Elisabeth Brouwer⁵, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Hanzeplein 1, UMCG, Groningen, Netherlands
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting
IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma
Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…
Abstract Number: 1469 • 2014 ACR/ARHP Annual Meeting
Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients
Masako Tsukamoto¹, Keiko Yoshimoto², Noriyuki Seta³, Katsuya Suzuki² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Keio university, Tokyo, Japan
Background/Purpose It is well known that circulating monocytes are the source of inflammatory cytokines, such as IL-6 and TNFα and newly divided into three subsets…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 3001 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Jerome Avouac¹, Lucille Desallais², Maxime Fréchet³, Muriel Elhai³, Jean François Zagury² and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, ³INSERM U1016, Cochin Institute, Paris, France
Background/Purpose: Interleukin 6 (IL-6) is a pleiotropic cytokine involved in inflammatory and autoimmune processes. Preliminary data have suggested that IL-6 might contribute to systemic sclerosis…
Abstract Number: 1015 • 2014 ACR/ARHP Annual Meeting
Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes
Tariq Haqqi¹, Abdul Haseeb² and Mohammad Shahidul Makki², ¹Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, ²Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH
Background/Purpose Post-transcriptional regulation of cytokine expression is important for maintaining tissue integrity. MCPIP1 was identified as a novel protein, which destabilizes inflammatory cytokines mRNAs via…
Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP^® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Seng-Lai Tan¹, Alison O'Mahony², Ellen L. Berg², Kandeepan Ganeshalingam³ and Ernest H. Choy⁴, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²BioSeek, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting
Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo
Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].